A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients.
Lena BöhnHans TörnblomLukas Van OudenhoveMagnus SimrénStine StörsrudPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
The use of α-galactosidase together with meals high in oligosaccharides was in this pilot study not superior to placebo in reducing postprandial GI symptoms or the concentration of hydrogen and methane in expired air in IBS.
Keyphrases
- placebo controlled
- double blind
- irritable bowel syndrome
- clinical trial
- end stage renal disease
- phase iii
- newly diagnosed
- phase ii
- study protocol
- liver failure
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- phase ii study
- randomized controlled trial
- blood glucose
- patient reported outcomes
- blood pressure
- type diabetes
- squamous cell carcinoma
- radiation therapy
- metabolic syndrome
- intensive care unit
- skeletal muscle
- adipose tissue
- physical activity
- hepatitis b virus
- drug induced
- patient reported